Mark Snell, DO
Family Medicine · Clinton, MONPI 1427025600
Payments from drug & device makers
Across 134 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$332
- Sunovion Pharmaceuticals Inc.$276
- Lilly USA, LLC$230
- Otsuka America Pharmaceutical, Inc.$177
- AbbVie$142
- Amgen$121
- plus $916 from 22 others
What the payments were for
- Food & beverage$2,189100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $332 |
| Sunovion Pharmaceuticals Inc. | 18 | $276 |
| Lilly USA, LLC | 16 | $230 |
| Otsuka America Pharmaceutical, Inc. | 11 | $177 |
| AbbVie | 8 | $142 |
| Amgen | 8 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $104 |
| Pfizer | 7 | $103 |
| Boehringer Ingelheim | 6 | $98 |
| Novartis | 6 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $59 |
| Mylan Specialty L.p. | 4 | $59 |
| Neurocrine Biosciences, Inc. | 3 | $50 |
| Abbott | 2 | $39 |
| Novo Nordisk | 2 | $38 |
| Johnson & Johnson | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Medtronic | 1 | $17 |
| Bayer | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Merck | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$2,195 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 361 | $186,413 |
| Austedo XrDeutetrabenazine | 41 | $154,790 |
| TrulicityDulaglutide | 137 | $147,652 |
| EliquisApixaban | 279 | $133,410 |
| XareltoRivaroxaban | 115 | $54,149 |
| OzempicSemaglutide | 32 | $33,676 |
| XcopriCenobamate | 25 | $31,246 |
| FarxigaDapagliflozin Propanediol | 45 | $27,771 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $23,950 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $22,304 |
| AustedoDeutetrabenazine | 16 | $21,838 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,533 |
| MounjaroTirzepatide | 17 | $20,140 |
| MyrbetriqMirabegron | 82 | $20,106 |
| RybelsusSemaglutide | 15 | $18,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $98 | $200,767382 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $230 | $167,792154 claims |
| PfizerEliquis, Abrysvo | $103 | $138,921296 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $27 | $72,268130 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $12 | $65,199128 claims |
| Novo NordiskOzempic, Rybelsus | $38 | $51,92947 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $332 | $48,30474 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $20,10682 claims |
| NovartisEntresto | $87 | $17,21426 claims |
| MerckJanuvia | $14 | $7,84412 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $59 | $5,88524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Clinton
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.